EP1056762A4 - GENETIC IMMUNIZATION WITH NON-STRUCTURAL PROTEINS OF HEPATITIS C VIRUS - Google Patents

GENETIC IMMUNIZATION WITH NON-STRUCTURAL PROTEINS OF HEPATITIS C VIRUS

Info

Publication number
EP1056762A4
EP1056762A4 EP99904381A EP99904381A EP1056762A4 EP 1056762 A4 EP1056762 A4 EP 1056762A4 EP 99904381 A EP99904381 A EP 99904381A EP 99904381 A EP99904381 A EP 99904381A EP 1056762 A4 EP1056762 A4 EP 1056762A4
Authority
EP
European Patent Office
Prior art keywords
hepatitis
virus
nonstructural proteins
genetic immunization
immunization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99904381A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1056762A1 (en
Inventor
Jack Wands
Jens Encke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP1056762A1 publication Critical patent/EP1056762A1/en
Publication of EP1056762A4 publication Critical patent/EP1056762A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
EP99904381A 1998-01-30 1999-01-28 GENETIC IMMUNIZATION WITH NON-STRUCTURAL PROTEINS OF HEPATITIS C VIRUS Withdrawn EP1056762A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7315698P 1998-01-30 1998-01-30
US73156P 1998-01-30
PCT/US1999/001823 WO1999038880A1 (en) 1998-01-30 1999-01-28 Genetic immunization with nonstructural proteins of hepatitis c virus

Publications (2)

Publication Number Publication Date
EP1056762A1 EP1056762A1 (en) 2000-12-06
EP1056762A4 true EP1056762A4 (en) 2003-07-23

Family

ID=22112053

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99904381A Withdrawn EP1056762A4 (en) 1998-01-30 1999-01-28 GENETIC IMMUNIZATION WITH NON-STRUCTURAL PROTEINS OF HEPATITIS C VIRUS

Country Status (9)

Country Link
EP (1) EP1056762A4 (ko)
JP (1) JP2002501737A (ko)
KR (2) KR20060057653A (ko)
CN (3) CN100335637C (ko)
AU (1) AU746258B2 (ko)
BR (1) BR9908540A (ko)
CA (1) CA2318744A1 (ko)
IL (1) IL137458A0 (ko)
WO (1) WO1999038880A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562346B1 (en) * 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
ATE376558T1 (de) * 1999-11-24 2007-11-15 Novartis Vaccines & Diagnostic Neues nichtstrukturelles hcv polypeptid
US6986892B1 (en) 1999-11-24 2006-01-17 Chiron Corporation Immunogenic Hepatitis C virus non-structural polypeptides
US7598362B2 (en) 2001-10-11 2009-10-06 Merck & Co., Inc. Hepatitis C virus vaccine
FR2855758B1 (fr) 2003-06-05 2005-07-22 Biomerieux Sa Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
WO2013062507A1 (en) * 2011-10-24 2013-05-02 The Trustees Of The University Of Pennsylvania Improved hcv vaccines and methods for using the same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
WO1996037606A1 (en) * 1995-05-22 1996-11-28 Bionova Corporation Compositions and methods for the diagnosis of, and vaccination against, hepatitis c virus (hcv)
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1997044469A2 (en) * 1996-05-24 1997-11-27 Chiron Corporation Multiple epitope fusion protein
WO1997047358A1 (en) * 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
WO1999029843A1 (en) * 1997-12-11 1999-06-17 Smithkline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE270326T1 (de) * 1990-04-04 2004-07-15 Chiron Corp Protease von hepatitis-c-virus

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016737A1 (en) * 1993-01-26 1994-08-04 Weiner David B Compositions and methods for delivery of genetic material
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1996037606A1 (en) * 1995-05-22 1996-11-28 Bionova Corporation Compositions and methods for the diagnosis of, and vaccination against, hepatitis c virus (hcv)
WO1997044469A2 (en) * 1996-05-24 1997-11-27 Chiron Corporation Multiple epitope fusion protein
WO1997047358A1 (en) * 1996-06-11 1997-12-18 Merck & Co., Inc. Synthetic hepatitis c genes
WO1999029843A1 (en) * 1997-12-11 1999-06-17 Smithkline Beecham Corporation Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHOO Q-L ET AL: "GENETIC ORGANIZATION AND DIVERSITY OF THE HEPATITIS C VIRUS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 88, 1 March 1991 (1991-03-01), pages 2451 - 2455, XP000652139, ISSN: 0027-8424 *
ENCKE J. ET AL.: "Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model", JOURNAL OF IMMUNOLOGY, vol. 161, no. 9, 1 November 1998 (1998-11-01), pages 4917 - 4923, XP002233910 *
INCHAUSPE G.: "Gene vaccination for hepatitis C", SPRINGER SEMINARS IN IMMUNOPATHOLOGY, vol. 19, no. 2, 1997, pages 211 - 221, XP008014824 *
INCHAUSPE G.: "Mechanism of protection in hepatitis C virus infection", MEDECINE ET MALADIES INFECTIEUSES, vol. 25, October 1995 (1995-10-01), pages 1067 - 1073, XP008017646 *
PAPA S. ET AL.: "Development of a multigenic plasmid vector for HCV DNA immunization", RESEARCH IN VIROLOGY, vol. 149, no. 5, September 1998 (1998-09-01), pages 315 - 319, XP002233911 *
SAITO T ET AL: "PLASMID DNA-BASED IMMUNIZATON FOR HEPATITIS C VIRUS STRUCTURAL PROTEINS: IMMUNE RESPONSES IN MICE", GASTROENTEROLOGY, vol. 112, no. 4, April 1997 (1997-04-01), pages 1321 - 1330, XP001013414, ISSN: 0016-5085 *
See also references of WO9938880A1 *
STUYVER L ET AL: "CLONING AND PHYLOGENETIC ANALYSIS OF THE CORE, E2, AND NS3/NS4 REGIONS OF THE HEPATITIS C VIRUS TYPE 5A+", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 202, no. 3, 1994, pages 1308 - 1314, XP002057873, ISSN: 0006-291X *

Also Published As

Publication number Publication date
AU2478699A (en) 1999-08-16
CN101126095A (zh) 2008-02-20
JP2002501737A (ja) 2002-01-22
KR20060057653A (ko) 2006-05-26
EP1056762A1 (en) 2000-12-06
WO1999038880A1 (en) 1999-08-05
KR20010086226A (ko) 2001-09-10
CN1289339A (zh) 2001-03-28
IL137458A0 (en) 2001-07-24
BR9908540A (pt) 2000-11-28
CA2318744A1 (en) 1999-08-05
KR100628411B1 (ko) 2006-09-28
CN100335637C (zh) 2007-09-05
AU746258B2 (en) 2002-04-18
CN101126094A (zh) 2008-02-20

Similar Documents

Publication Publication Date Title
PL324906A1 (en) Vaccines against viral hepatitis of c type
ZA981838B (en) Functional DNA clone for hepatitis C virus (HCV) and uses thereof
DE60014345D1 (en) Makrozyklische peptide als hepatitis c virus ns3 protease inhibitore
PL321966A1 (en) Vaccine against viral hepatitis of b type
AU2055301A (en) Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
DK1001801T3 (da) Produkt omfattende mindst en dobbeltkædet RNA kombineret med mindst et interferon til behandling af viral hepatitis
AP2001002301A0 (en) Inhibition of viral infection using monovalentantigen-binding proteins
AU5285899A (en) Anti hepatitis c virus antibody and uses thereof
AU6371900A (en) Lactam inhibitors of hepatitis c virus ns3 protease
ZA9811316B (en) Novel hepatitis C virus NS5B protein
AU2933797A (en) Synthetic inhibitors of hepatitis c virus ns3 protease
EP1627917A4 (en) A NUCLEIC ACID CONSTRUCTED FROM THE GENE OF HEPATITIS C-VIRUS (HCV) GENOTYP 2A NUCLEIC ACID CELL AND CELL WITH THE NUCLEIC ACID CONSTRUCTED THEREIN
EP0998585A4 (en) SCREENING METHOD USING AN ATPASE PROTEIN FROM A VIRUS OF THE i (FLAVIVIIDAE) FAMILY
AU7602800A (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
HK1062579A1 (en) A fusion protein for treatment of hepatitis b virus and its use thereof
EP1141255A4 (en) MODIFIED FORMS OF HEPATITIS C VIRUS NS3 PROTEASE
AU2001246331A1 (en) Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof
EP0747482A3 (en) Recombinant hepatitis GB virus proteins their uses
IL137458A0 (en) Genetic immunization with nonstructural proteins of hepatitis c virus
EP1100545A4 (en) REGULATED EXPRESSION OF RECOMBINANT PROTEINS USING RNA VIRUSES
IL138804A0 (en) Hepatitis c virus ns5b nucleic acids and proteins
EP1113777A4 (en) NOVEL HEPATITIS C VIRUS PEPTIDES AND USES THEREOF
AU9494998A (en) (in vivo), animal model for expression of hepatitis c virus
ZA964094B (en) Compositions and methods for the diagnosis of and vaccination against hepatitis c virus (hcv)
EP1521849A4 (en) HEPATITIS A-VIRUS NUCLEOTIDE SEQUENCES, RECOMBINANT PROTEINS AND THEIR USE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000830

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 07K 14/18 B

Ipc: 7A 61K 39/29 B

Ipc: 7A 61K 39/12 B

Ipc: 7C 12N 15/85 B

Ipc: 7C 12N 5/10 B

Ipc: 7C 12N 15/51 B

Ipc: 7C 07H 21/04 B

Ipc: 7C 07H 21/02 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030604

17Q First examination report despatched

Effective date: 20040824

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20080602